Cellyan Biotechnology Co., Ltd cash flow to debt ratio of 23.97% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Cellyan Biotechnology Co., Ltd's free cash flow has increased -185.88% from $-482.35K last year to $414.23K, signaling increasing performance

Cellyan Biotechnology Co., Ltd's debt to equity ratio is 0.44, which means that the company's assets are healthy financed, signaling financial stability.

Cellyan Biotechnology Co., Ltd's debt has decreased relative to shareholder equity from 0.49 last year to 0.44 today, signaling strengthened financials

Cellyan Biotechnology Co., Ltd has a net cash position, so leverage is healthy.

Cellyan Biotechnology Co., Ltd's interest coverage ratio is -13.84, which means that the company struggles to meet interest obligations, signaling financial risk.

Cellyan Biotechnology Co., Ltd's profit margin has decreased (153.84%) in the last year from 7.97% to -4.29%, signaling decreasing performance

Cellyan Biotechnology Co., Ltd's short-term assets of $8.73M exceed its short-term liabilities of $2.92M

Cellyan Biotechnology Co., Ltd's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cellyan Biotechnology Co., Ltd's return on equity of -13.85%, is lower than 15.00%, indicating bad performance

Cellyan Biotechnology Co., Ltd's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cellyan Biotechnology Co., Ltd has insufficient public price history to evaluate earnings stability.

Cellyan Biotechnology Co., Ltd has positive free cash flow, indicating the company generates cash after capital expenditures

Cellyan Biotechnology Co., Ltd has a free cash flow yield of 8.99%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

Cellyan Biotechnology Co., Ltd's yearly earnings has decreased 102.03% since last year from $1.33M to $-27.06K, signaling decreasing performance

Cellyan Biotechnology Co., Ltd's yearly revenue has increased 21.72% since last year from $16.69M to $20.31M, signaling increasing performance

ROIC -8.91% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cellyan Biotechnology Co., Ltd has insufficient revenue history to calculate 3-year revenue CAGR.

Cellyan Biotechnology Co., Ltd has insufficient public price history to evaluate revenue consistency.

Cellyan Biotechnology Co., Ltd has insufficient public price history to evaluate ROE consistency.

Cellyan Biotechnology Co., Ltd has insufficient data to evaluate this check.

Cellyan Biotechnology Co., Ltd has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cellyan Biotechnology Co., Ltd is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cellyan Biotechnology Co., Ltd has an EV/EBITDA ratio of 3.29x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings

Cellyan Biotechnology Co., Ltd has insufficient data to evaluate this check.

Cellyan Biotechnology Co., Ltd has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cellyan Biotechnology Co., Ltd has a price-to-book ratio of 0.90x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Cellyan Biotechnology Co., Ltd has a price-to-sales ratio of 0.28x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue